Compare VC & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VC | SLS |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | 10000 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.7B |
| IPO Year | 2000 | 2007 |
| Metric | VC | SLS |
|---|---|---|
| Price | $100.90 | $11.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 1 |
| Target Price | ★ $125.50 | $10.00 |
| AVG Volume (30 Days) | 314.7K | ★ 6.9M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | N/A | ★ 50.00 |
| EPS | ★ 2.93 | N/A |
| Revenue | ★ $3,768,000,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $5.21 | $110.98 |
| P/E Ratio | $34.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $83.49 | $1.39 |
| 52 Week High | $128.15 | $15.88 |
| Indicator | VC | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 39.76 | 52.10 |
| Support Level | $99.98 | $12.64 |
| Resistance Level | $107.65 | $15.77 |
| Average True Range (ATR) | 2.75 | 1.12 |
| MACD | -0.27 | -0.09 |
| Stochastic Oscillator | 23.13 | 29.70 |
Visteon Corp is an automotive supplier. It manufactures electronics products for original equipment vehicle manufacturers including Ford, Nissan, Renault, Mazda, BMW, General Motors, and Honda, etc. The company offers information displays, instrument clusters, head-up displays, infotainment systems, telematics solutions, and Smartcore. The company's reportable segment is Electronics. The Electronics segment provides vehicle cockpit electronics products to customers, including digital instrument clusters, domain controllers with integrated driver assistance systems, displays, Android-based infotainment systems, and battery management systems. Geographically, it operates in North America, Europe, China, Asia-Pacific, and South America.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.